BNTC news

Latest 3 stories · newest Oct 28, 2026

BNTC

Benitec: 100% responder rate in OPMD Gene Therapy Study

Benitec Biopharma announced 100% responder rates for high and low dose BB-301; interim high dose results showed superior improvements in swallowing function needed to advance towards a pivotal trial.

Regulatory Oct 28, 2026 sentiment +0.80 SEC filing ↗

BNTC

Benitec Announces FDA Type C Meeting Feedback for BB-301 Pivotal Study

The FDA has requested additional data, including OPMD natural history study results, but confirmed the pivotal trial remains on track to begin enrolling patients in mid-2027.

Regulatory Oct 5, 2026 sentiment -0.30 SEC filing ↗

BNTC

Baker Tilly confirms auditor change effective Sept 2026

Baker Tilly US, LLP, the former independent auditor of Benitec Biopharma Inc., issued a statement confirming the disclosure of its separation as the company's certifying accountant and agreeing with the September 24, 2026, Form 8-K filing details.

Leadership Sep 24, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same BNTC feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/BNTC/newsSTART FREE